Welcome to our dedicated page for Springworks Therapeutics SEC filings (Ticker: SWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial footnotes, R&D cost drivers, milestone payments, and FDA status hide deep in SpringWorks Therapeutics’ multi-section 10-K. For analysts chasing desmoid-tumor data or confirming cash runway before the next pivotal read-out, scrolling hundreds of biotech pages wastes hours. The challenge intensifies when insider activity posts on Form 4 minutes after market close. Investors need answers fast, not another PDF.
Stock Titan surfaces what matters the instant an SWTX document hits EDGAR. Our AI-powered summaries translate scientific jargon and accounting detail into plain English, delivering real-time filing updates as they’re published to EDGAR. Whether you’re reviewing a SpringWorks Therapeutics quarterly earnings report 10-Q filing, scanning an unexpected 8-K material event, or comparing figures in the latest SpringWorks Therapeutics proxy statement executive compensation disclosure, our platform highlights pipeline updates, royalty obligations, and cash burn without line-by-line reading.
Every filing type is covered:
- SpringWorks Therapeutics insider trading Form 4 transactions with alert history
- SpringWorks Therapeutics quarterly earnings report 10-Q filing trend charts
- SpringWorks Therapeutics executive stock transactions Form 4 in real time
- SpringWorks Therapeutics annual report 10-K simplified for quick reference
- SpringWorks Therapeutics 8-K material events explained
- Understanding SpringWorks Therapeutics SEC documents with AI
Stop guessing when executives sell shares or when milestone payments hit the balance sheet. With expert annotations, keyword search across all SpringWorks Therapeutics filings, and side-by-side PDF comparison, you get SpringWorks Therapeutics earnings report filing analysis in seconds—clarity and speed every time the company presses “submit.”
Goldman Sachs Group, Inc. and its affiliate Goldman Sachs & Co. LLC report beneficial ownership of 4,234,033.35 shares of SpringWorks Therapeutics common stock, representing 5.6% of the class. The filing shows the positions are held with shared voting power (4,233,899.35 shares) and shared dispositive power (4,234,021.35 shares), and no sole voting or dispositive power is reported. The statement certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing includes a joint filing agreement and identifies Goldman Sachs & Co. LLC as a subsidiary of the parent reporting entity.
Hudson Bay Capital Management LP and Sander Gerber report beneficial ownership of 3,936,857 shares of SpringWorks Therapeutics, representing 5.22% of the outstanding common stock. The reported position includes 3,529,200 shares issuable upon exercise of call options. The filings show no sole voting or dispositive power and shared voting and dispositive power of 3,936,857 shares, indicating the securities are held in the name of the fund managed by the Investment Manager.
The Schedule 13G filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The ownership percentage is calculated using an outstanding share base of 75,348,995 shares as disclosed in the company proxy.
FAQ
What is the current stock price of Springworks Therapeutics (SWTX)?
What is the market cap of Springworks Therapeutics (SWTX)?
